Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach

Current formulations of combined oral contraceptives (COC) containing ethinylestradiol (EE) have ≤35 μg due to increased risks of cardiovascular diseases (CVD) with higher doses of EE. Low‐dose formulations however, have resulted in increased incidences of breakthrough bleeding and contraceptive fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezuruike, Udoamaka, Humphries, Helen, Dickins, Maurice, Neuhoff, Sibylle, Gardner, Iain, Rowland Yeo, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282492/
https://www.ncbi.nlm.nih.gov/pubmed/29637542
http://dx.doi.org/10.1002/cpt.1085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282492/
https://www.ncbi.nlm.nih.gov/pubmed/29637542
http://dx.doi.org/10.1002/cpt.1085

Ejemplares similares